Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Lophos Pharmaceuticals Corp., a Canadian psychedelic research company is scheduled to present at the upcoming Lift & Co. Expo next week, Friday, May 13th. The feature presentation titled, “Nature’s Medicine: Peyote’s Place in the Psychedelic Industry,” is scheduled for 11:30am.
Claire Stawnyczy, President & CEO of Lophos Pharma, will present her plan to create sustainable peyote cultivation and affiliated chemical compound research. The presentation will elaborate on peyote’s place in the psychedelic industry, and how peyote’s traditional use should be responsibly and sustainably researched using modern techniques.
“I look forward to sharing how Lophos’ will take what we’ve learned in cannabis cultivation and apply it to the responsible cultivation of peyote, as well as describing the research we intend for the peyote plant and its chemical derivatives.” – Claire Stawnyczy.
In her presentation, Claire will help unpack what peyote is, why the endangered cactus is important to indigenous peoples, and why it is worthy of cultivation research to enhance conservation efforts. The presentation will also include information on what makes this plant unique, the challenges of cultivating peyote, and of course; how Lophos Pharma plans to play a key role in the future of peyote and peyote-derived pharmaceuticals.
For more information please contact:
Cushion Communications Inc.
Lophos is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug development. We develop novel therapies and natural health treatments that aim to restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques, Lophos Pharmaceuticals will provide our partners with medical grade inputs and our patients with access to safe and effective mescaline-based therapeutics.
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company’s psychedelics program. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123473